1型糖尿病残存胰岛功能保护——免疫治疗
郑帅,顾愹,杨涛
摘要(Abstract)：
<正>1型糖尿病(type 1 diabetes mellitus,T1DM)是一种慢性自身免疫性疾病,抗原特异性、致病性T细胞攻击胰岛导致分泌胰岛素的β细胞特异性破坏,引起临床高血糖症状。典型的T1DM在患者出现临床症状时已丧失大部分胰岛,仅有15%~20%的β细胞存活[1]。从自身免疫性糖尿病的自然病程来看,β细胞的自身免疫性破坏在高
关键词(KeyWords)：
基金项目(Foundation): 国家自然科学基金(30971405,81270897)
作者(Author): 郑帅,顾愹,杨涛
参考文献(References)：
- [1]Karlsson FA,Berne C,Bjork E,et al.Beta-cell activity and destruction in type 1 diabetes[J].Ups J Med Sci,2000,105(2):85-95.
- [2]Greenbaum CJ,Mandrup-Poulsen T,McGee PF,et al.Mixedmeal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1diabetes[J].Diabetes Care,2008,31(10):1966-1971.
- [3]Saudek F,Havrdova T,Boucek P,et al.Polyclonal anti-T-cell therapy for type 1 diabetesmellitus of recent onset[J].Rev Diabet Stud,2004,1(2):80-88.
- [4]Chatenoud L,Bluestone JA.CD3-specific antibodies:a portal to the treatment ofautoimmunity[J].Nat Rev Immunol,2007,7(8):622-632.
- [5]Chatenoud L,Thervet E,Primo J,et al.Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice[J].Proc Natl Acad Sci USA,1994,91(1):123-127.
- [6]Herold KC,Hagopian W,Auger JA,et al.Anti-CD3 monoclonal antibody in new-onset type 1 diabetesmellitus[J].N Engl J Med,2002,346(22):1692-1698.
- [7]Herold KC,Gitelman SE,Ehlers MR,et al.Teplizumab(antiCD3 mAb)treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial:Metabolic and immunologic features at baseline identify a subgroup of responders[J].Diabetes,2013,62(11):3766-3774.
- [8]Pescovitz MD,Greenbaum CJ,Bundy B,et al.B-Lymphocyte Depletion with Rituximab and Beta-Cell Function:Two-Year Results[J].Diabetes Care,2013[Epub ahead of print].
- [9]Orban T,Bundy B,Becker DJ,et al.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes:a randomised,double-blind,placebo-controlled trial[J].Lancet,2011,378(9789):412-419.
- [10]Mastrandrea L,Yu J,Behrens T,et al.Etanercept treatment in children with new-onset type 1 diabetes:pilot randomized,placebo-controlled,double-blind study[J].Diabetes Care,2009,32(7):1244-1249.
- [11]Dinarello CA,Simon A,van der Meer JW.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases[J].Nat Rev Drug Discov,2012,11(8):633-652.
- [12]Moran A,Bundy B,Becker DJ,et al.Interleukin-1 antagonism in type 1 diabetes of recent onset:two multicentre,randomised,double-blind,placebo-controlled trials[J].Lancet,2013,381(9881):1905-1915.
- [13]Ludvigsson J,Faresj M,Hjorth M,et al.GAD treatment and insulin secretion in recent-onset type 1diabetes[J].N Engl J Med,2008,359(18):1909-1920.
- [14]Ludvigsson J,Krisky D,Casas R,et al.GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus[J].N Engl J Med,2012,366(5):433-442.
- [15]Thrower SL,James L,Hall W,et al.Proinsulin peptide immunotherapy in type 1 diabetes:report of a first-in-man Phase I safety study[J].ClinExp Immunol,2009,155(2):156-165.
- [16]Roep BO,Solvason N,Gottlieb PA,et al.Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+T cells in type 1 diabetes[J].Sci Transl Med,2013,5(191):191ra82.
- [17]Schloot NC,Meierhoff G,Lengyel C,et al.Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1:two prospective,randomized,double-blind phase II trials[J].Diabetes Metab Res Rev,2007,23(4)276-285.
- [18]Buzzetti R,Cernea S,Petrone A,et al.C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy withDiaPep277:an exploratory study[J].Diabetes,2011,60(11):3067-3072.
- [19]Gottlieb PA,Quinlan S,Krause-Steinrauf H,et al.Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type1 diabetes[J].Diabetes Care,2010,33(4):826-832.
- [20]Rother KI,Spain LM,Wesley RA,et al.Effects of exenatide alone and in combination with daclizumab onbeta-cell function in long-standing type 1 diabetes[J].Diabetes Care,2009,32(12):2251-2257.
- [21]Long SA,Rieck M,Sanda S,et al.Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairsβ-cell function[J].Diabetes,2012,61(9):2340-2348.
- [22]Bresson D,Togher L,Rodrigo E,et al.Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs[J].J Clin Invest,2006,116(5):1371-1381.
- [23]Bresson D,Fradkin M,Manenkova Y,et al.Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy innew-onset type 1diabetes[J].Mol Ther,2010,18(2):307-316.
- [24]Sherry NA,Chen W,Kushner JA,et al.Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3monoclonal antibody by enhancing recovery of beta-cells[J].Endocrinology,2007,148(11):5136-5144.